R&D / Pipeline Opportunities
Hemophilia A

    Hemophilia A is the most well-known genetic bleeding disorder caused by either mutation or complete deficiency of blood clotting factor VIII. Bleeding into joints, muscles, brain, and other organs occur in people with severe hemophilia A after minor injury or even there is no injury., with heavy bleeding seen during surgery. Hemophilia A patients are generally treated with replacement therapy, in which the missing clotting FVIII is replaced with plasma-derived or recombinant FVIII molecules. The plasma-derived FVIII products are the first replacement products used in Hemophilia treatment, but due to a number of disadvantages, plasma-derived products are gradually being replaced with new, and in some cases, novel forms of recombinant FVIII.  However, the high costs of recombinant FVIII in the treatment of hemophilia A bleeding episodes, especially when used in prophylaxis, are unattainable to the average vulnerable patient and their families, especially in some areas of the world.


    To address the current unmet medical need, wehave developed a novel manufacturing technology (Patents are granted in both US and China, as well as applications in other countries) for recombinant human factor VIII, which will bring a revolutionary change in the treatment landscape for hemophilia A patients.

  With our exciting new process, the recombinant FVIII expression level has been increased significantly more than the production levels currently achievable by other companies and with the highest quality and specific activity - this will make the drug more generally available and considerably more affordable on a commercial scale. We recently completed three successful GMP production runs at the 200L scale, and based on the actual cost, we believe that the recombinant FVIII can be made for a few cents per international unit of FVIII, and possibly even less, depending on the scale.

Our therapeutic pipeline includes therapies to treat bleeding in hemophilia A and von Willebrand disease, acute bleeding in other traumatic indications, reducing thrombotic events in related pathologies and targeting to eliminate cancer, including metastatic tumors.

Novel Tumor-targeting Therapy

   Off-target effects of immunotherapy result in systemic toxicity that is still the major side effect of current cancer therapy. To be effective and safe,
targeted immunotherapy in tumor treatment has been developed rapidly in recent years and has greatly improved the prognosis for, and longevity of, cancer patients. We have established a unique nano-antibody platform and have prepared a variety of anti-tumor fusion proteins based on this technology to selectively target a tumor's microenvironment. This unique targeting mechanism, specific to the tumor microenvironment, holds great promise as a novel therapeutic approach for the treatment of a broad range of primary tumors and metastatic disease, particularly for tumors that lack specific molecular epitopes suitable for drug targeting.
Pipeline Map and Opportunities
Pursuing innovation
          and excellence
13th Kechuang St. Beijing Economic Development Area, Beijing
Passionate for life and future Dedicated to the research and development in the area of hemostasis, thrombosis, rare diseases and cancer therapies.